Morgan Stanley analyst Terence Flynn maintained a Hold rating on Pfizer (PFE – Research Report) today and set a price target of $30.00.

Good day, everyone, and welcome to Pfizer's third quarter 2024 earnings conference call. Today's call is being recorded. At ...

Reports Q3 revenue $17.7B, consensus $14.95B. Dr. Albert Bourla, Chairman and Chief Executive Officer, stated: “We delivered another ...

Pfizer's oncology revenues jumped 30 percent in the third quarter, with growth from several precision oncology drugs.

Pfizer's Q3 earnings soar on COVID revenue but stock dips as market doubts long-term growth. See why I think that 2025 will not be a strong year for PFE stock.

Pfizer (PFE) stock fell even as the company beat forecasts with its Q3 results and increased its full-year outlook.Find out ...

Pfizer’s third-quarter revenue and adjusted profit exceeded expectations, driven by strong sales of its Covid vaccine and ...

Pfizer stock is down Tuesday even after the drugmaker reported higher-than-expected Q3 earnings and raised its full-year ...

Pfizer PFE reported third-quarter 2024 adjusted earnings per share of $1.06, which crushed the Zacks Consensus Estimate of 64 ...

CEO Albert Bourla, who is under attack from activist investor Starboard Value, got a much-needed victory on Tuesday as Pfizer ...

Pfizer's third-quarter performance exceeded expectations, driven by a surge in demand for its COVID-19 treatment Paxlovid, ...

Pfizer reported an adjusted EPS of $1.06, exceeding estimates by over 72%. Revenue reached $17.7 billion, marking a 32% year ...